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Introduction. The existence of human cardiac stem cells (hCSC) and their regenerative capacity are not fully deﬁned. The aim of
this study was to identify and analyse the distribution of hCSCs by ﬂow cytometry (FCM). Methods. Tissue samples from the left
ventricle (LV) and the appendages of the right atrium (RA) and left atrium (LA) were taken during cardiac surgery. Mononuclear
cells (MNCs) were isolated, labelled for the stem-cell-marker c-kit and hematopoietic-lineage markers and analysed by FCM.
Results. HCSCs could be isolated from the RA, LA, and LV without signiﬁcant quantitative diﬀerence between both atria (A)
(RA4.80 ± 1.76%versusLA4.99 ± 1.69% of isolated MNCs, P = 0.922). The number of hCSCs was signiﬁcantly higher in both
atria compared to the left ventricle (A4.90 ± 1.29%versusLV0.62 ± 0.14% of isolated MNCs, P = 0.035). Conclusion. The atria
contain a higher concentration of hCSC than the left ventricle. HCSCs located in the atria could serve as an endogenous source for
heart regeneration.
1.Introduction
Despite various treatment options, heart failure is still the
leading cause for mortality and morbidity in the elderly. In
the last years stem cell transplantation for the purpose of
cardiac regeneration was successful in experimental studies.
Diverse pluripotent endogenous adult stem cells were
tested for their impact on myocardial regeneration [1–4].
Clinical trials focussed on bone-marrow-derived stem cells
to initiate cardiac regeneration and showed an improvement
of cardiac function [5]. Nevertheless, the search for more
applicable cells with a better outcome still continues.
The human heart has always been deﬁned as a postmi-
totic organ with a determined number of cardiomyocytes
(CMs) formed during the embryonic and foetal life. Thus,
it was assumed that if the heart loses a number of CMs, the
remaining cells would have to sustain the heart function.
The identiﬁcation of human cardiac stem cells (hCSC)
revealed the heart’s own capacity for regeneration. Further-
more, it was reported that cell turnover occurs in the human
heart [1]. This suggests that the CMs undergo apoptosis at a
certain rate and are regenerated by hCSCs.
The existence of hCSC was reported by several re-
searchers,buttheirorigin,function,andpossibletherapeutic
beneﬁt are still under discussion [6].
The cardiac distribution of hCSCs in patients with heart
diseases, a basic requirement for their therapeutic use in the
future, is not yet determined.
Therefore, the aim of the present study was to investigate
the distribution of hCSC in diﬀerent compartments of the
heart with the help of ﬂow cytometry.
2.MaterialsandMethods
Myocardial tissue samples (n = 20) were taken from the
left ventricle (LV), the appendages of the right atrium (RA)
and left atrium (LA) from adult patients undergoing cardiac
surgery. The average age of the patients was 67 ± 2y e a r s .
The samples were taken during aortic valve replacement,
mitral valve repair/replacement, and coronary artery bypass
surgery. The samples weight was 0.36 ±0.09g.
To conﬁrm the FCM results, several tissue samples were
additionally analysed by immunohistochemistry. This study
was approved by the local ethical committee and followed2 ISRN Cardiology
the rules of the Helsinki Declaration for patient dates and
evaluation. Informed consent was given by the patients.
2.1. Flow Cytometry. The tissue samples were weighed and
washed several times in Hank’s Balanced Salt Solution,
followed by a sequential digestion with collagenase IV and
trypsin (15min, 37◦C, 0.2mg/mL). The cell suspensions
were ﬁltered using cell strainer (100μm, 70μm, and 40μm)
and MNCs were isolated by density gradient centrifugation.
These cells were stained with speciﬁc antibodies (100μLc e l l s
suspension + 5μL of each antibody incubated for 20min.)
for stem cell marker c-kit (Polyclonal rabbit Anti-Human
CD 117, Dako) and the hematopoietic lineage markers CD3,
CD11b, CD19, and CD45 (antihuman, BD Biosciences). The
nuclei of the cells were labelled with draq 5 (Biostatus,
0.5μL was added 10min. after the other antibodies). Cell
characteristics were analysed using a LSR II ﬂow cytometer
(BD Biosciences, San Jose, CA).
2.2. Immunohistochemistry. The tissue samples were ﬁxed
in 4% Phosphate buﬀered saline buﬀered formalin and
embedded in paraﬃn.
For immunoﬂuorescence staining, the sections were
deparaﬃnized in xylene, rehydrated in alcohol series (1 ×
10 minutes 100%, 1 × 10 minutes 96%, and 1 × 10 minutes
76%), dried for 10 minutes, rehydrated for 5 minutes in
distilled water, and washed in Tris Buﬀered Saline (TBS)
for 10 minutes. Antigen retrieval was performed by boiling
the section in Na-Citrate (10mmol/L) for 30min. using a
microwave (30min. at 800 Watt). The sections were cooled
down for 30min., before they were washed in TBS for 10
minutes and blocked with 4% milk/TBS for 1h at room
temperature. Subsequently, the sections were incubated with
the primary antibody (Polyclonal rabbit antihuman CD 117,
c-kit, Dako) over night at 4◦C. On the following day, the
sections were washed three times for 5 minutes in Tris-
NaCl-Tween-Buﬀer (TNT). The sections were blocked with
TNB-Buﬀer (TNT buﬀer containing blocking reagent) for
30 minutes and incubated with a secondary antibody (Goat-
Anti Rabbit, Dianova) for 30 minutes at room temperature.
They were washed in TNT-Buﬀer for 3 × 5m i n u t e sa n d
treated with biotinylated tyramid for 10 minutes. The
sections were washed in distilled water and mounted with
Fluorescent Dako.
Quantitative and qualitative histological analyses were
performed using an Axioplan2 microscope (Carl Zeiss
GmbH, Jena, Germany) and the KS 300 Imaging System 3.0
(Carl Zeiss Vision GmbH, Eching, Germany).
2.3. Statistical Analyses. The multivariate data analysis was
performed by FACS Diva software (BD Biosciences, San Jose,
CA). All data are expressed as mean and ± SEM. Statistical
comparison was performed by one-way ANOVA followed
by paired t-test as appropriated. Results were considered
statistically signiﬁcant as P<0.05. All data analyses
were performed by using SAS software, version 6.11 (SAS
Institute, Cary, NC, USA).
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Figure 1: FCM analysis of c-kit/lineage of atrial tissue.
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Figure 2: FCM analysis of c-kit/lineage of left ventricular tissue.
3. Results
3.1. Flow Cytometry. With the mentioned approach, we
could isolate MNCs from heart tissue and identify c-kitpos
cells in all samples. We detected human cardiac stem cells
which were c-kitpos and lineageneg in all investigated heart
compartments (Figures 1 and 2).
There is no signiﬁcant quantitative diﬀerence of c-kitpos
and linageneg cells between both atria (A) (RA 4.80 ±
1.76% versus LA 4.99 ± 1.69% of isolated MNCs, P =
0.922, Figure 3). The number of c-kitpos and linageneg cells
was signiﬁcantly higher in both atria compared to the left
v e n t r i c l e( A4 .90 ±1.29% versus LV 0.62 ±0.14% of isolated
MNCs, P = 0.035, Figure 3).ISRN Cardiology 3
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Figure 3 :( a )C o m p a r i s o no fc - k i t pos/linneg cells between the right (RA) and left atrium (LA), (b) Comparison of c-kitpos/linneg cells between
the atria (A) and left ventricle (LV).
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Figure 4: c-kit positive cells embedded in myocardial tissue; (a) left atrium, (b) right atrium, (c) left ventricle.
3.2. Immunohistochemistry. The immunohistochemical
staining showed c-kitpos cells in all investigated heart
compartments and conﬁrmed the distribution shown by
FCM analysis (Figure 4).
4. Discussion
Several reports support the existence of cardiac stem cells
in the adult heart, but only a few studies used human
tissue samples. In this study, we report the presence and
distribution of human cardiac stem cells deﬁned by the
expression of the cell surface antigen c-kit and the absence
of hematopoietic lineage markers in patients undergoing
cardiac surgery.
Our data support other reports about a c-kit-positive
population of cardiac stem cells and extend these ﬁndings
by showing a signiﬁcant diﬀerence in the cell distribution
between the atria and the left ventricle.
Many clinical studies investigated the inﬂuence of stem
cell transplantation on heart function after myocardial4 ISRN Cardiology
infarction or cardiomyopathy. After the initial demonstra-
tion of safety, especially bone-marrow-derived stem cells
were used in clinical trials to initiate cardiac regeneration [7–
12]. Other studies using growth factor or other stimulating
factors demonstrated similar eﬀects [13]. Both approaches
lead to an improvement in heart function. Whether these
eﬀects are due to transdiﬀerentiation into CMs, induction
of angiogenesis, or paracrine eﬀects on hCSCs is still under
discussion [14]. Maybe all three mechanisms are involved
[15].
Current investigations focus on ﬁnding the ideal cell type
for cell therapy as each one has its own beneﬁts and disad-
vantages.
Bone-marrow-derived stem cells (BMCs) are easy to gain
and their transplantation leads to a light improvement of
cardiacfunctionforabout2yearsandreducestheoccurrence
of major adverse cardiovascular events [16, 17]. Lin et al.
reported that endothelial progenitor cells (EPCs) derived
from bone marrow play an important role in angiogenesis
[18]. It could be shown that erythropoietin improves cardiac
function by homing and incorporating EPCs into the
myocardial microvasculature and myocardial secretion of
angiogenic factors [19].
ButasEPCsonlyseemtoimprovevascularization,regen-
eration of the heart by creation of new CMs is not expected.
It was reported that skeletal myoblasts can diﬀerentiate
into viable muscle ﬁbres within the scarred tissue after
transplantation [20]. However, in a clinical trial myoblast
transfer did not improve LV function compared to placebo,
but increased the number of early postoperative arrhythmic
events [21].
Ii et al. showed that adipose-derived stem cells also
exhibit a therapeutic eﬀect on cardiac preservation following
myocardial infarction [22]. This positive eﬀect is not due
to transdiﬀerentiation of the cells. One explanation may
be the production of growth factors like VEGF, bFGF, and
SDF-1αshowingparacrineeﬀectsbysupportingendogenous
progenitor cell recruitment to ischemic myocardium [22].
Another study by Gaebel et al. showed that bone-marrow-
derived human mesenchymal stem cells initiate a greater
cardiac improvement in comparison to those from adipose
tissue [23].
Cardiac stem cells represent a promising source for cell
therapyastheyseemtobethephysiologicaldepotforcardiac
regeneration. A high regenerative potency and low risk for
arrhythmias are assumed.
If the hCSCs origin is really in the myocard or if these
cells are provided by the bone marrow is not clear yet,
but at least a part of hCSCs seem to have their origin in
the bone marrow [15]. Regeneration implies that dead cells
are replaced by newly formed cells restoring the original
structure of the organ. It was shown that hCSCs can
diﬀerentiate in vitro and in vivo to myocyte, smooth muscle
and endothelial cell lineages [24].
In adulthood, this occurs during physiological cell
turnover, but myocardial damage could stimulate the diﬀer-
entiation of resident hCSCs into de novo cardiomyocytes.
Mishra et al. recently reported that hCSCs are abundant
in the neonatal period and decrease over time [25]. Our
observed diﬀerences in distribution support this hypothesis
asthetransdiﬀerentiationofhCSCswouldprimarilyoccurin
the ventricle where a loss of CMs is more likely. The reduced
amount of hCSCs explains the hearts inability to regenerate
in the elderly and could be the reason why the beneﬁt of stem
cell transplantation is limited.
Consequently, increasing the number of hCSCs may
boost the regenerative capability of the heart. As several
reports showed an improvement of heart function after the
injectionofhCSCsintheheart,atherapeuticapproachcould
be to isolate hCSCs, expand them in vitro, and transplant
them back to the same patient [26–28].
Another option could be the injection of substances
leading to a migration and/or proliferation of CSCs. Linke
et al. and Rota et al. reported that the activation of resident
CSCs by hepatocyte growth factor and insulin-like growth
factor-1 as well as the injection of CSCs in the heart leads to
de novo myocytes and vascular structures [13, 27].
Tang et al. reported that the injection of exogenous CSCs
activates endogenous CSCs and is beneﬁcial in the setting of
an old myocardial infarction [29].
Additionally, the positive eﬀects on contractile behaviour
seem to be independent of the CSC donors age. Thus, CSCs
could be the ideal cell for cardiac regeneration [30].
5. Conclusion
Cell therapy is a promising strategy to treat heart failure,
as it aims to regenerate the myocardium with contractile
substance. Up to now, the ideal cell type is still unknown.
Since the discovery of CSCs, researchers investigate diﬀerent
ways of using these cells for cardiac regeneration. As far
as we know, this is the ﬁrst report about the distribution
of hCSC in the diﬀerent compartments of the heart. We
show that the concentration of CSCs is higher in the atria
than in the ventricle. This suggests the use of the atria
as the origin for CSC gaining. As myocardial infarctions
usually hit the ventricle, the atria could serve as a source for
cardiac regeneration. Therefore, the arrhythmogenic impact
and potential for diﬀerentiation of these cells should be
investigated.
StudyLimitations
As it is diﬃcult to gain tissue samples from patients without
heart disease, we could not compare our ﬁndings with a
healthycontrolgroup.Duetothelimitednumberofsamples,
our results are preliminary. We could not detect if there is
a correlation between the patients disease and the number
of hCSCs. Furthermore we did not investigate the function,
multipotency, and self-renewing ability of the cells.
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